Allogeneic transplant replaces blood formation and adds donor immunity
Allogeneic transplantation uses blood-forming stem cells from a donor after conditioning therapy. It can provide a graft-versus-leukemia or graft-versus-tumour effect, which is central to its curative potential.
The same donor immune system can attack normal tissues, causing graft-versus-host disease. Infection, organ toxicity, graft failure, relapse and prolonged recovery make timing and centre experience important.
Disease status, transplant risk, conditioning choice, infection control, caregiver support and post-transplant access matter alongside HLA compatibility.
Who may be considered?
Specialist review may help when the source diagnosis and treatment timeline raise a practical question about donor stem-cell transplant.
- High-risk leukemia or MDS where transplant may reduce relapse risk.
- Selected lymphoma, marrow-failure or inherited blood disorders.
- A patient with adequate disease control and organ reserve.
- Someone requiring related, unrelated, haploidentical or cord donor review.
- A second opinion on timing, conditioning or relapse prevention.
What the specialist team must confirm
The transplant team reviews disease risk and response, HLA typing and donor options, age and frailty, heart lung kidney and liver function, infection and antibody screening, fertility goals, psychosocial readiness and the ability to remain near the centre.
Key points for this treatment
From donor search to immune recovery
The sequence is planned around disease urgency, donor availability, conditioning risk and the resources required after infusion.
Engraftment, graft-versus-host disease and relapse prevention
Early follow-up tracks blood-count recovery, infection, organ function and acute graft-versus-host disease. Immunosuppression is adjusted carefully to balance graft tolerance and disease control.
Long-term care includes vaccination, chronic GVHD assessment, endocrine and bone health, fertility, secondary-cancer risk and relapse monitoring.
Limits, burdens and realistic expectations
Transplant can cause treatment-related death, graft failure, severe infection, infertility, organ damage and acute or chronic GVHD. Relapse can still occur. Recovery may take many months, and emergency specialist access is essential.
Fever, new rash, severe diarrhoea, jaundice, breathing difficulty, confusion or inability to take transplant medicines requires urgent transplant-team contact.